Tanabe Pharma America announced the finalization of the transfer of the RADICAVA (edaravone) business to Shionogi Inc. (SI). TPA previously announced the transfer on December 22, 2025. This critical milestone ensures continued strength and strategic alignment for RADICAVA, a leading therapy for amyotrophic lateral sclerosis (ALS).
Effective immediately, the RADICAVA business, including intellectual property rights and marketing rights in key countries and regions, has officially transitioned to SI. For certain countries and regions, rights will be transferred sequentially following the prescribed procedures. This strategic move supports the long-term growth and sustainability of the brand by solidifying RADICAVA's future within a company recognized for its commitment to the research and development of innovative medicines that address unmet medical needs for people worldwide.
"We are incredibly proud of the achievements we have accomplished in bringing RADICAVA to patients living with ALS, and today marks both a meaningful milestone and an exciting new beginning," said Yasutoshi Kawakami, President, TPA. "This finalization allows TPA to focus on driving discoveries through innovative science with a late-stage pipeline of investigational treatments for difficult-to-treat diseases."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!